Roar Biomedical develops, manufactures and markets novel fluorescence-based methods for drug discovery and clinical research. Established in 1997, Roar specializes in techniques to measure the activity of enzymes directly involved in lipid metabolism. These lipid active proteins play a central role in the development of cardiovascular disease.

Our proprietary techniques are cited in over 150 scientific publications and our cholesteryl ester transfer protein (CETP) and lecithin:cholesterol acyltransferase (LCAT) assays are used in human clinical trials to monitor the effect of drugs on these proteins.

Roar’s innovations include plasma CETP activity assays that are not affected by endogenous lipoprotein concentrations. The assays enable monitoring the primary effect of a CETP inhibitor rather than changes in a secondary marker. Roar supports research studies at several academic institutions.

We are located in New York City at Columbia University's Audubon Biomedical Center. In 2006, the company opened a new laboratory at Stony Brook University’s Calverton incubator.